Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TYMP | P19971 | 1/20 | 0.40 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17833859 | 0.89 | POLB (0.47) | POLA1KDM4ETAS1R3TAS1R1TYMP | |
| SCHEMBL12729570 | 0.85 | SLC29A1 (0.47) | — | |
| SCHEMBL17834988 | 0.85 | SLC29A1 (0.47) | — | |
| SCHEMBL12729601 | 0.82 | KDM4E (0.39) | POLA1KDM4ETAS1R3TAS1R1 | |
| SCHEMBL12729615 | 0.81 | CYP1A2 (0.43) | POLA1PNPLMNATP53HTT | |
| SCHEMBL25507075 | 0.78 | KDM4E (0.72) | POLA1KDM4ETAS1R3TAS1R1PNP | |
| SCHEMBL264545 | 0.78 | KDM4E (0.72) | POLA1KDM4ETAS1R3TAS1R1PNP | |
| SCHEMBL12714741 | 0.78 | KDM4E (0.72) | POLA1KDM4ETAS1R3TAS1R1PNP | |
| SCHEMBL20346237 | 0.78 | KDM4E (0.72) | POLA1KDM4ETAS1R3TAS1R1PNP | |
| SCHEMBL264546 | 0.78 | KDM4E (0.72) | POLA1KDM4ETAS1R3TAS1R1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168636-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-20160168636-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-9163053-B2 | Nucleotide analogs | FLUIDIGM CORPORATION (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163053-B2 | Nucleotide analogs | FLUIDIGM CORPORATION (US) | 2015-10-20 | — | — | US | disclosed |
| US-20110081647-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081647-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081647-A1 | NUCLEOTIDE ANALOGS | DUT, NT5C2, NUDT21 | POLA1 100/4885KDM4E 1828/4885TAS1R3 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.